

COMPUTATIONAL DIGITAL PATHOLOGY DIAGNOSIS: AI APPLICATIONS AND IMMUNOPATHOLOGY

Dr. YU Weimiao
Bioinformatics Institute, A*STAR

April 26, 2021

The content of this presentation are protected by copyright, trademark and other forms of proprietary rights. All rights, title and interest in the Contents are owned by, licensed to or controlled by A*STAR. You shall not reproduce, publish, upload, post, transmit, adapt, modify or otherwise display, distribute or exploit in any way, without the prior written permission of A*STAR.











Overview of the research directions:

Al-based digital pathology diagnosis

ImmunoPathology:

Acknowledgement









Overview of the research topics


2D/3D Cellular Segmentation: Cell-by-cell quantitative information






Published in Cytometry Part A and Bioinformatics

Understanding the Control mechanism of Embryonic Polarisation







Overview of the research topics


(100)












Licensed to Singapore Biotech Company

MORPHEA n = 7;


Histoindex Analysis


Skin Disease collagen Signature




Licensed to Singapore Biotech Company


Discover the digital prognosis feature for TNBC patients







Published in Breast Cancer Research, highlighted by A*STAR Research




Under Review

(1001)







Overview of the research topics



Al based completed diagnosis pipeline for TCT diagnosis






Under Revision of Nature Communication













Developed tools, partners and application fields

Developed Tools Library

Image Management

- Archiving
- Compression
- Image Stitching
- Image Overlap

Image Analysis

- Annotation
- Segmentation
- Feature extraction
- Profiling

Apps Library - Disease Oriented Solutions



Mitosis detection

Cancer

Gleason Grade

Prostate cancer

TMN Stage

Breast cancer



PD-1 & PDL-1 analysis

Prostate cancer Prognosis

Subtype

Partnership



Equipment Suppliers

- Perkin Elmer
- Leica
- Phillips



Reagent Suppliers

- Ultivue
- Akoya
- Leica
- Perkin Elmer



Pathology Labs

- NUH
- SGH
- TTSH
- Parkway
- Etc

Target Market

Research

Academic & Pharma

Clinical


Confirmation Diagnostics
Prognosis
Treatment Selection
Prediction of Response

Commercial

Instrument Companies
Al Biotech Companies
Cloud Providers

Tech Innovation Validation Commercialisation










Structural annotation of large DP images with quality control

DP image quality control



DP annotation



Example: Gleason score: 7(3+4)







Dr Hue Swee Shan Susan







Prostate Cancer and problem statement

Prostate cancer biopsies are time consuming and tedious routine job in clinical pathology department. The needs in clinical:

- 1. Differentiate malignant and benign biopsy samples, which is often of large amount.
- 2. Provide prediction using Al to guild the pathologist to provide more accurate and reliable staging score.

Prostate cancer risk assessment

Gleason Score: established pathology

High Gleason Score (HGS): > 6

Low Gleason Score(**LGS**): ≤6

Other factors: Age, PSA, etc

Gleason score

The sum of the most commonly found pattern and the second most commonly found pattern

Low risk GS≤6

Active

surveillance

Repeated Biopsy (H&E)

Prostate cancer screening

DRE, PSA

Localized

Intermediate risk GS:7

Radiation

therapy

Biopsy (H&E)

DRE or MRI


Advanced

Metastatic diseases

High risk GS>7

Radical

prostatectomy



Medical Treatment


Active surveillance

scoring system for disease prognosis

























	All 88 slides			s		
	G3	G4	G5	N/	S	
No. of patches	8492	17371	1391	3545	5286	
			Ţ			
	G3	G4	G5	N	S	
Train (62 slides)	6109	12282	1038	2638	3699	
Test (26 slides)	2383	5089	353	907	1587	







Impact of the scale



Example: 11257_14_A13

Gleason Score: 9 (4+5)




			(,,,		
Patch Size	Gleason 3	Gleason 4	Gleason 5	Normal	Stroma
2001*2001	82.1	76.3	28.9	70.0	97.1
1001*1001	79.6	76.8	38.9	74.6	97.1
501*501	78.2	67.1	64.9	74.5	91.6

(1001)






Impact of confidence level



Gleason score: 8(4+4)

17045_08_S1 Ground Truth





Predictions

(1001)









Example: P9099_D18_Scan1

Gleason score: 7(3+4)

























































Biomedical Research & Development

- High quality sample & data generation for R&D
- Customised service for big Pharma and local Biotech












ImmunoPathology Diagnosis











CD68

PD-L1



**


ImmunoPathology Diagnosis CD8 CD68 PD-L1 PAN CK Pro Tumour Macrophage Immune Evading Carcinoma PD-L1 DAPI CD8 CD68 PAN CK Immune Evading Carcinoma Pro Tumour Macrophage

























Example panCK/SoX10+ neighbourhood





Acknowledgement















Changi General Hospital SingHealth













